Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2009

- Updated Survival and Biomarker Data for Ipilimumab to be Presented -

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an anti-PD-1 antibody for cancer treatment, have been selected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 29-June 2, 2009 in Orlando:

Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

  • "Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #9008, Developmental Therapeutics: Immunotherapy Session) O. Hamid - Oral presentation from 1:00 p.m. to 4:15 p.m. local time on Saturday, May 30, 2009.

  • "Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #3031, Developmental Therapeutics: Immunotherapy Session) S. Parker - General poster from 8:00 a.m. to 12:00 p.m. local time on Saturday, May 30, 2009.

  • "Effect of ipilimumab treatment on 18-month survival: update of patients with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials" (Abstract #9033, Melanoma Session) S. O'Day - Poster discussion from 8:00 a.m. to 12:00 p.m. local time on Sunday, May 31, 2009.

  • "Immunologic impact of anti-CTLA-4 therapy" (Abstract #3019, Development Therapeutics: Immunotherapy Session) P. Sharma - Poster discussion from 2:00 p.m. to 6:00 p.m. local time on
    '/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Medarex to Present at the RBC Capital Markets Healthcare Conference
6. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
7. Medarex Announces 2008 Third Quarter Financial Results
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. Medarex to Present at the UBS Global Life Sciences Conference
10. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
11. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):ADA releases updated position paper on nutrient supplementation 2UAB bone center director wins distinguished service award from clinical pathology society 2MSU researcher unveils new approach to treat lower back pain 2Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 1Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 2Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 3Chicago area Infertility Specialist Richard Sherbahn MD Reports a Woman 26apos 3Bs Age Affects Her Chances of Successful Pregnancy from Egg Donation 47869 4Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 1Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 2Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 47864 3Protein may be strongest indicator of rare lung disease study shows 47859 1Protein may be strongest indicator of rare lung disease study shows 47859 2